GeoVax Labs (NASDAQ:GOVX) Stock Price Down 4.8%

GeoVax Labs, Inc. (NASDAQ:GOVX)’s share price fell 4.8% during trading on Tuesday . The company traded as low as $1.50 and last traded at $1.60. 51,493 shares changed hands during trading, an increase of 35% from the average session volume of 38,109 shares. The stock had previously closed at $1.68.

GeoVax Labs Stock Performance

The company has a market cap of $3.48 million, a PE ratio of -0.12 and a beta of 2.90. The stock’s 50-day simple moving average is $2.14 and its 200 day simple moving average is $4.82.

Hedge Funds Weigh In On GeoVax Labs

A number of institutional investors and hedge funds have recently made changes to their positions in GOVX. Armistice Capital LLC acquired a new stake in GeoVax Labs in the 4th quarter valued at about $587,000. Renaissance Technologies LLC grew its stake in GeoVax Labs by 160.3% in the 3rd quarter. Renaissance Technologies LLC now owns 1,045,526 shares of the company’s stock valued at $1,140,000 after acquiring an additional 643,897 shares during the last quarter. BlackRock Inc. grew its stake in GeoVax Labs by 104,042.1% in the 3rd quarter. BlackRock Inc. now owns 413,444 shares of the company’s stock valued at $451,000 after acquiring an additional 413,047 shares during the last quarter. Vanguard Group Inc. lifted its holdings in GeoVax Labs by 112.5% in the 3rd quarter. Vanguard Group Inc. now owns 549,966 shares of the company’s stock valued at $600,000 after purchasing an additional 291,200 shares in the last quarter. Finally, State Street Corp lifted its holdings in GeoVax Labs by 659.4% in the 3rd quarter. State Street Corp now owns 168,142 shares of the company’s stock valued at $183,000 after purchasing an additional 146,000 shares in the last quarter. 6.09% of the stock is owned by institutional investors and hedge funds.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.